While C-19 has taken a toll on near-term earnings, it has necessitated actions to reduce costs and eliminate non-core activities, setting the business up well for a more positive environment. The better than expected balance sheet position at June trumps our lower earnings forecasts and we maintain a BUY call on a $0.42 valuation (prior $0.44).
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.
